References
- Wicker S , Maltezou HC . Vaccine-preventable diseases in Europe: Where do we stand?. Expert Rev Vaccines. 2014; 13(8): 979–87.
- Ehreth J . The global value of vaccination. Vaccine. 2003; 21(7–8): 596–600.
- Beutels P . Economic evaluation of vaccination programmes in humans: A methodological exploration with application to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination. 2002; Antwerp: University of Antwerp.
- Antonova EN , Rycroft CE , Ambrose CS , Heikkinen T , Principi N . Burden of paediatric influenza in Western Europe: A systematic review. BMC Public Health. 2012; 12: 968.
- Glaser K , Montserrat ER , Waginger U , Price D , Stuchbury R , Tinker A . Grandparenting in Europe and the US. Available from: http://www.gulbenkian.org.uk/files/13-12-10-FP5 Grandparenting in Europe Summary_Grandparents Plus.pdf [cited 1 December 2014].
- Dex S , Joshi H . Millennium Cohort Study first survey: A user's guide to initial findings. Available from: http://eprints.ioe.ac.uk/5933/1/MCS1_A_Users_Guide_To_Initial_Findings.pdf [cited 1 December 2014].
- Bonanni P , Boccalini S , Bechini A , Banz K . Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: The burden of uncomplicated hospitalised cases. Vaccine. 2008; 26: 5619–26.
- De Wals P , Blackburn M , Guay M , Bravo G , Blanchette D , Douville-Fradet M . Burden of chickenpox on families: A study in Quebec. Can J Infect Dis. 2001; 12: 27–32.
- Coudeville L , Brunot A , Giaquinto C , Lucioni C , Dervaux B . Varicella vaccination in Italy: An economic evaluation of different scenarios. Pharmacoeconomics. 2004; 22: 839–55.
- Banz K , Wagenpfeil S , Neiss A , Hammerschmidt T , Wutzler P . The burden of varicella in Germany. Potential risks and economic impact. Eur J Health Econ. 2004; 5: 46–53.
- Van der Wielen M , Giaquinto C , Gothefors L , Huelsse C , Huet F , Littmann M et al . Impact of community-acquired paediatric rotavirus gastroenteritis on family life: Data from the REVEAL study. BMC Fam Pract. 2010; 11: 22.
- Loeppke R , Nicholson S , Taitel M , Sweeney M , Haufle V , Kessler RC . The impact of an integrated population health enhancement and disease management program on employee health risk, health conditions, and productivity. Popul Health Manag. 2008; 11(6): 287–96.
- OECD. Health at a glance 2011: OECD indicators. Available from: http://www.oecd.org/els/health-systems/49105858.pdf [cited 9 December 2014].
- World Health Organisation. The global burden of disease: 2004 update. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=1 [cited 9 December 2014].
- Barnighausen T , Bloom DE , Cafiero-Fonseca ET , O'Brien JC . Valuing vaccination. Proc Natl Acad Sci USA. 2014; 111(34): 12313–9.
- Soriano-Gabarro M , Mrukowicz J , Vesikari T , Verstraeten T . Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J. 2006; 25(1 Suppl): S7–11.
- Harris JP , Jit M , Cooper D , Edmunds WJ . Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine. 2007; 25(20): 3962–70.
- Giaquinto C , Van Damme P , Huet F , Gothefors L , Van der Wielen M . Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: The REVEAL study. J Infect Dis. 2007; 195(Suppl 1): S36–44.
- Huet F , Largeron N , Trichard M , Miadi-Fargier H , Jasso-Mosqueda G . Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq in France. Vaccine. 2007; 25(34): 6348–58.
- Public Health England. Meningococcal disease: Guidance, data and analysis. Available from: http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733822509 [cited 10 December 2014].
- Trotter CL , Edmunds WJ . Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ. 2002; 324(7341): 809.
- Kaye P , Malkani R , Martin S , Slack M , Trotter C , Jit M et al . Invasive pneumococcal disease (IPD) in England & Wales after 7-valent conjugate vaccine (PCV7): Potential impact of 10 and 13-valent vaccines. Available form: http://webarchive.nationalarchives.gov.uk/20140714084352; http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1245581527892 [cited 11 December 2014].
- Gleizes O , Desselberger U , Tatochenko V , Rodrigo C , Salman N , Mezner Z et al . Nosocomial rotavirus infection in European countries: A review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J. 2006; 25(1 Suppl): S12–21.
- van Seventer R , Sadosky A , Lucero M , Dukes E . A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing. 2006; 35(2): 132–7.
- Charfi R , El Aidli S , Zaiem A , Kastalli S , Srairi S , Daghfous R et al . Adverse drug reactions in older adults: A retrospective study from pharmacovigilance. Therapie. 2012; 67(5): 471–6.
- IARC. European code against cancer. Available from: http://cancer-code-europe.iarc.fr/index.php/en/ecac-12-ways [cited 11 December 2014].
- Blank PR , Schwenkglenks M , Sardos CS , Patris J , Szucs TD . Population access to new vaccines in European countries. Vaccine. 2013; 31(27): 2862–7.
- Ricciardi GW , Toumi M , Weil-Olivier C , Ruitenberg E , Dankó D , Duru G et al . Comparison of NITAG policies and working processes in selected developed countries. Vaccine. 2015; 33(1): 3–11. doi: http://dx.doi.org/10.1016/j.vaccine.2014.09.023 .
- Duclos P . National Immunization Technical Advisory Groups (NITAGs): Guidance for their establishment and strengthening. Vaccine. 2010; 28(Suppl 1): A18–25.